304:
422:, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof." This standard lies at the heart of the regulatory program for drugs. Data for the submission must include those from one or more rigorous clinical trials.
31:
483:
The documentation required in an NDA is supposed to tell "the drug’s whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged.” Once
479:
package insert or Full
Prescribing Information. The prescribing information is widely available on the web from the FDA, drug manufacturers, and frequently inserted into drug packages. The main purpose of a drug label is to provide healthcare providers and consumers with adequate information and
538:(ANDA), which does not require all of the clinical trials normally required for a new drug in an NDA. Most biological drugs, including a majority of recombinant proteins are considered ineligible for an ANDA under current US law. However, a handful of biologic medicines, including biosynthetic
425:
Due to the plural "adequate and well-controlled investigations" in the statute, FDA has interpreted the substantial evidence requirement as requiring at least two adequate and well-controlled clinical trials, each convincing on its own. However, in 1997, Congress passed an amendment, expressly
487:
Once the application is submitted, the FDA has 60 days to conduct a preliminary review, which assesses whether the NDA is "sufficiently complete to permit a substantive review." If the FDA finds the NDA insufficiently complete, then the FDA rejects the application by sending the applicant a
390:(IND) designation from FDA. This application is based on nonclinical data, typically from a combination of in vivo and in vitro laboratory safety studies, that shows the drug is safe enough to test in humans. Often the "new" drugs that are submitted for approval include
214:
330:) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. Some 30% or less of initial drug candidates proceed through the entire multi-year process of
436:
Phase 2: The drug is tested for both efficacy and safety in up to several hundred people with the targeted disease. Some two-thirds of candidate drugs fail in Phase 2 clinical trials due to the drug not being as effective as
459:
The legal requirements for safety and effectiveness have been interpreted as requiring scientific evidence that the benefits of a drug outweigh the risks and that adequate instructions exist for use, since many drugs have
562:
under governance of the
Federal Food Drug and Cosmetics Act, because these products were already approved when legislation to regulate biotechnology medicines later passed as part of the Public Health Services Act.
1055:
290:
815:
797:
283:
528:(BLA), rather than an NDA. The manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process.
337:
The goals of the NDA are to provide enough information to permit FDA reviewers to establish the complete history of the candidate drug. Among facts needed for the application are:
276:
1064:
229:
61:
1052:
262:
76:
106:
898:
492:
letter, which explains where the application failed to meet requirements. Where the application cannot be granted for substantive reasons, the FDA issues a
426:
granting FDA authority to consider other types of confirmatory evidence along with one adequate and well-controlled clinical investigation for approval.
574:(NADA). These are also specifically evaluated for their use in food animals and their possible effect on the food from animals treated with the drug.
1104:
433:
Phase 1: The drug is tested in 20 to 100 healthy volunteers to determine its safety at low doses. About 70% of candidate drugs advance to Phase 2.
816:"Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence"
713:
925:"Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance for Treatment of Acute Pain and Fever"
257:
455:
trials in several thousand people taking the drug for its intended purpose to monitor efficacy and safety of the approved marketed drug.
868:
932:
1089:
846:
56:
234:
116:
1079:
1025:
688:
1030:
899:"FINDINGS: Issues and Communication: Independent Evaluation of FDA's First Cycle Review Performance – Final Report"
535:
186:
1109:
1053:
Chapter 11: Prescription Drug
Product Submissions in: Fundamentals of US Regulatory Affairs, Eighth Edition 2013
902:
605:
440:
Phase 3: The drug is typically tested in several hundred to several thousand people with the targeted disease in
121:
71:
524:, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a
394:
or old medications that have been chemically modified to elicit differential pharmacological effects or reduced
567:
484:
approval of an NDA is obtained, the new drug can be legally marketed starting that day in the United States.
448:
controlled trials to demonstrate its specific efficacy. Under 30% of drug candidates succeed through Phase 3.
407:
962:
525:
319:
312:
252:
111:
602:, a 1962 amendment to the Federal Food, Drug, and Cosmetic Act (e.g. to also require evidence of efficacy)
1099:
571:
176:
169:
452:
355:
475:
The results of the testing program are codified in an FDA-approved public document that is called the
1084:
599:
224:
219:
88:
66:
593:
521:
493:
387:
159:
705:
984:
766:
744:
655:
386:
To legally test the drug on human subjects in the United States, the maker must first obtain an
869:"Merck KGaA Receives Refuse To File Letter From FDA On Cladribine Tablets New Drug Application"
81:
628:
303:
678:
42:
798:"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products"
566:
Medications intended for use in animals are submitted to a different center within FDA, the
1094:
534:
that have already been approved via an NDA submitted by another maker are approved via an
410:, new drugs are statutorily required to demonstrate both safety and effectiveness through
8:
588:
391:
1020:
876:
1035:
684:
181:
38:
347:
Drug safety and specific effectiveness for its proposed use(s) when used as directed
1016:
1012:
924:
583:
375:
331:
191:
149:
418:
as "evidence consisting of adequate and well-controlled investigations, including
1059:
842:
509:
361:
543:
419:
367:
351:
164:
139:
1073:
559:
555:
461:
308:
196:
30:
531:
441:
1047:
1039:
1043:
832:
21 CFR 201.5: Labeling
Requirements for Prescription Drugs and/or Insulin
464:
395:
144:
551:
547:
767:"The Drug Development Process. Step 1: Discovery and Development"
539:
445:
954:
374:
Exceptions to this process include voter driven initiatives for
350:
Reports on the design, compliance, and conclusions of completed
680:
341:
745:"The Drug Development Process. Step 3: Clinical Research"
656:"The Drug Development Process. Step 4: FDA Drug Review"
507:
implies an FDA decision within about 10 months while a
787:
Food, Drug, and
Cosmetic Act, Section 505; 21 USC 355]
769:. U.S. Food and Drug Administration. January 4, 2018
747:. U.S. Food and Drug Administration. January 4, 2018
658:. U.S. Food and Drug Administration. January 4, 2018
631:. U.S. Food and Drug Administration. January 4, 2018
516:
429:
The trials are typically conducted in three phases:
24:
Regulation of therapeutic goods in the United States
334:, concluding with an approved NDA, if successful.
1071:
901:. Food and Drug Administration. Archived from
985:"C&EN: COVER STORY - BEYOND HATCH-WAXMAN"
499:Assuming the FDA finds the NDA acceptable, a
284:
739:
737:
735:
733:
731:
650:
648:
646:
843:"Daily Med:Current Medication Information"
596:, FDA application to start clinical trials
291:
277:
29:
1011:
706:"Public Health Focus - FDA and Marijuana"
480:directions for the safe use of the drug.
470:
1105:United States federal health legislation
891:
835:
759:
728:
703:
643:
623:
621:
307:A new drug application in the 1930s for
302:
107:Department of Health and Human Services
1072:
849:from the original on November 12, 2008
16:Request US FDA approve new medications
618:
670:
414:for approval. The amendment defines
57:Federal Food, Drug, and Cosmetic Act
955:"FDA, CDER Office of Generic Drugs"
781:
716:from the original on April 28, 2018
676:
235:Single Convention on Narcotic Drugs
13:
935:from the original on July 11, 2017
401:
14:
1121:
1026:Concise Encyclopedia of Economics
1005:
965:from the original on May 28, 2009
517:Requirements for similar products
513:should complete within 6 months.
1031:Library of Economics and Liberty
536:Abbreviated New Drug Application
381:
187:Abbreviated New Drug Application
977:
947:
917:
861:
826:
608:, rules in different countries.
606:Regulation of therapeutic goods
72:Prescription Drug Marketing Act
808:
790:
697:
629:"The Drug Development Process"
568:Center for Veterinary Medicine
247:Non-governmental organizations
1:
1065:Novel Drug Approvals for 2021
704:Commissioner, Office of the.
612:
344:and manufacturing information
1090:Food and Drug Administration
526:Biologic License Application
320:Food and Drug Administration
313:Food and Drug Administration
253:National Academy of Medicine
112:Food and Drug Administration
7:
577:
572:New Animal Drug Application
177:Randomized controlled trial
10:
1126:
453:postmarketing surveillance
356:Institutional Review Board
209:International coordination
1080:American medical research
822:. FDA. November 30, 2023.
683:. John Wiley & Sons.
600:Kefauver Harris Amendment
408:Kefauver–Harris Amendment
220:Uppsala Monitoring Centre
89:Marihuana Tax Act of 1937
67:Controlled Substances Act
804:. FDA. January 27, 2020.
677:Gad, Shayne Cox (2008).
594:Investigational New Drug
494:Complete Response Letter
388:Investigational New Drug
370:) and directions for use
160:Investigational New Drug
420:clinical investigations
360:Drug susceptibility to
1110:Biotechnology products
1058:March 4, 2016, at the
471:The actual application
392:new molecular entities
315:
43:Over-the-counter drugs
311:to the United States
306:
117:Department of Justice
873:medicalnewstoday.com
416:substantial evidence
412:substantial evidence
324:New Drug Application
155:New Drug Application
589:Inverse benefit law
451:Phase 4: These are
378:in certain states.
366:Proposed labeling (
192:Fast track approval
101:Government agencies
1100:Experimental drugs
1021:David R. Henderson
316:
39:Prescription drugs
1013:Henninger, Daniel
376:medical marijuana
301:
300:
182:Pharmacovigilance
1117:
1085:Drug development
1034:
1029:(1st ed.).
1000:
999:
997:
995:
981:
975:
974:
972:
970:
951:
945:
944:
942:
940:
921:
915:
914:
912:
910:
905:on March 8, 2010
895:
889:
888:
886:
884:
879:on March 5, 2010
875:. Archived from
865:
859:
858:
856:
854:
839:
833:
830:
824:
823:
812:
806:
805:
794:
788:
785:
779:
778:
776:
774:
763:
757:
756:
754:
752:
741:
726:
725:
723:
721:
701:
695:
694:
674:
668:
667:
665:
663:
652:
641:
640:
638:
636:
625:
584:Drug development
503:is published. A
332:drug development
293:
286:
279:
150:Drug development
77:Hatch-Waxman Act
33:
21:
20:
1125:
1124:
1120:
1119:
1118:
1116:
1115:
1114:
1070:
1069:
1060:Wayback Machine
1008:
1003:
993:
991:
983:
982:
978:
968:
966:
953:
952:
948:
938:
936:
923:
922:
918:
908:
906:
897:
896:
892:
882:
880:
867:
866:
862:
852:
850:
841:
840:
836:
831:
827:
814:
813:
809:
796:
795:
791:
786:
782:
772:
770:
765:
764:
760:
750:
748:
743:
742:
729:
719:
717:
702:
698:
691:
675:
671:
661:
659:
654:
653:
644:
634:
632:
627:
626:
619:
615:
580:
519:
510:priority review
505:standard review
473:
406:Since the 1962
404:
402:Clinical trials
384:
352:clinical trials
297:
268:
267:
248:
240:
239:
210:
202:
201:
135:
127:
126:
102:
94:
93:
52:
41:
17:
12:
11:
5:
1123:
1113:
1112:
1107:
1102:
1097:
1092:
1087:
1082:
1068:
1067:
1062:
1050:
1007:
1006:External links
1004:
1002:
1001:
976:
946:
916:
890:
860:
834:
825:
807:
789:
780:
758:
727:
696:
689:
669:
642:
616:
614:
611:
610:
609:
603:
597:
591:
586:
579:
576:
544:growth hormone
518:
515:
490:Refuse to File
477:product label,
472:
469:
457:
456:
449:
438:
434:
403:
400:
383:
380:
372:
371:
368:package insert
364:
358:
348:
345:
299:
298:
296:
295:
288:
281:
273:
270:
269:
266:
265:
260:
255:
249:
246:
245:
242:
241:
238:
237:
232:
227:
222:
217:
211:
208:
207:
204:
203:
200:
199:
194:
189:
184:
179:
174:
173:
172:
165:Clinical trial
162:
157:
152:
147:
142:
140:Drug discovery
136:
133:
132:
129:
128:
125:
124:
119:
114:
109:
103:
100:
99:
96:
95:
92:
91:
86:
85:
84:
74:
69:
64:
59:
53:
50:
49:
46:
45:
35:
34:
26:
25:
15:
9:
6:
4:
3:
2:
1122:
1111:
1108:
1106:
1103:
1101:
1098:
1096:
1093:
1091:
1088:
1086:
1083:
1081:
1078:
1077:
1075:
1066:
1063:
1061:
1057:
1054:
1051:
1049:
1045:
1041:
1037:
1032:
1028:
1027:
1022:
1018:
1014:
1010:
1009:
990:
986:
980:
964:
960:
956:
950:
934:
930:
926:
920:
904:
900:
894:
878:
874:
870:
864:
848:
844:
838:
829:
821:
817:
811:
803:
799:
793:
784:
768:
762:
746:
740:
738:
736:
734:
732:
715:
711:
707:
700:
692:
690:9780470259801
686:
682:
681:
673:
657:
651:
649:
647:
630:
624:
622:
617:
607:
604:
601:
598:
595:
592:
590:
587:
585:
582:
581:
575:
573:
569:
564:
561:
560:grandfathered
557:
556:hyaluronidase
553:
549:
545:
541:
537:
533:
532:Generic drugs
529:
527:
523:
514:
512:
511:
506:
502:
501:74-day letter
497:
495:
491:
485:
481:
478:
468:
466:
463:
454:
450:
447:
443:
439:
435:
432:
431:
430:
427:
423:
421:
417:
413:
409:
399:
397:
393:
389:
382:Before trials
379:
377:
369:
365:
363:
359:
357:
353:
349:
346:
343:
340:
339:
338:
335:
333:
329:
325:
321:
314:
310:
309:sulfapyridine
305:
294:
289:
287:
282:
280:
275:
274:
272:
271:
264:
261:
259:
256:
254:
251:
250:
244:
243:
236:
233:
231:
228:
226:
223:
221:
218:
216:
213:
212:
206:
205:
198:
197:Off-label use
195:
193:
190:
188:
185:
183:
180:
178:
175:
171:
168:
167:
166:
163:
161:
158:
156:
153:
151:
148:
146:
143:
141:
138:
137:
131:
130:
123:
120:
118:
115:
113:
110:
108:
105:
104:
98:
97:
90:
87:
83:
80:
79:
78:
75:
73:
70:
68:
65:
63:
60:
58:
55:
54:
48:
47:
44:
40:
37:
36:
32:
28:
27:
23:
22:
19:
1024:
992:. Retrieved
989:pubs.acs.org
988:
979:
967:. Retrieved
958:
949:
937:. Retrieved
928:
919:
909:February 23,
907:. Retrieved
903:the original
893:
881:. Retrieved
877:the original
872:
863:
851:. Retrieved
837:
828:
819:
810:
801:
792:
783:
771:. Retrieved
761:
749:. Retrieved
718:. Retrieved
709:
699:
679:
672:
660:. Retrieved
633:. Retrieved
565:
530:
520:
508:
504:
500:
498:
489:
486:
482:
476:
474:
465:side effects
458:
442:double-blind
437:anticipated.
428:
424:
415:
411:
405:
396:side effects
385:
373:
336:
327:
323:
317:
154:
18:
1095:Drug safety
853:October 10,
820:www.fda.gov
802:www.fda.gov
710:www.fda.gov
570:(CVM) in a
145:Drug design
1074:Categories
1017:"Drug Lag"
613:References
552:calcitonin
82:exemptions
1048:163149563
1040:317650570
994:April 30,
969:April 30,
939:April 30,
929:drugs.com
883:April 30,
720:April 30,
522:Biologics
322:'s (FDA)
1056:Archived
1044:50016270
1015:(2002).
963:Archived
933:Archived
847:Archived
714:Archived
578:See also
548:glucagon
1023:(ed.).
959:fda.gov
540:insulin
462:adverse
446:placebo
354:by the
134:Process
1038:
773:May 1,
751:May 1,
687:
662:May 1,
635:May 1,
554:, and
342:Patent
170:phases
62:CDAPCA
1019:. In
362:abuse
263:NORML
258:RADAR
230:CIOMS
1036:OCLC
996:2018
971:2018
941:2018
911:2010
885:2018
855:2007
775:2018
753:2018
722:2018
685:ISBN
664:2018
637:2018
558:are
318:The
328:NDA
225:WHO
215:ICH
122:DEA
51:Law
1076::
1046:,
1042:,
987:.
961:.
957:.
931:.
927:.
871:.
845:.
818:.
800:.
730:^
712:.
708:.
645:^
620:^
550:,
546:,
542:,
496:.
467:.
444:,
398:.
1033:.
998:.
973:.
943:.
913:.
887:.
857:.
777:.
755:.
724:.
693:.
666:.
639:.
326:(
292:e
285:t
278:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
